Characteristics and outcomes of selected studies
| Treatment | Mortality | Stroke or systemic embolism | Major bleeding | Intracranial bleeding | Gastrointestinal bleeding | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Year | A | B | Total | A | B | Follow-up | A | B | A | B | A | B | A | B | A | B |
| AFASAK | 1989 | Warfarin | Placebo | 671 | 335 | 336 | 2 years | 3/335 | 17/336 | 5/335 | 21/336 | 21/335 | 0/336 | 1/335 | 0/336 | NA | NA |
| SPAF | 1991 | Warfarin | Placebo | 421 | 210 | 211 | 1.3 years | 6/210 | 8/211 | 6/210 | 18/211 | 4/210 | 4/211 | 1/210 | 0/211 | NA | NA |
| EAFT | 1993 | Warfarin | Placebo | 439 | 225 | 378 | 2.3 years | 41/225 | 99/378 | 21/225 | 99/378 | 13/225 | 4/378 | 0/225 | 1/378 | 4/225 | 1/378 |
| AFASAK | 1989 | Warfarin | Aspirin | 671 | 335 | 336 | 2 years | 3/335 | 15/336 | 5/335 | 20/336 | 21/335 | 2/336 | 1/335 | 0/336 | 4/335 | 1/336 |
| EAFT | 1993 | Warfarin | Aspirin | 629 | 225 | 404 | 2.3 years | 41/225 | 102/404 | 21/225 | 94/404 | 13/225 | 6/404 | 0/225 | 1/404 | NA | NA |
| SPAF II | 1994 | Warfarin | Aspirin | 385 | 197 | 188 | 2 years | 26/197 | 24/188 | 21/197 | 21/188 | NA | NA | 7/197 | 3/188 | NA | NA |
| AFASAK II | 1999 | Warfarin | Aspirin | 339 | 170 | 169 | 3 years | 17/170 | 14/169 | 12/170 | 10/169 | 4/170 | 5/169 | 1/170 | 1/169 | NA | NA |
| PATAF | 1999 | Warfarin | Aspirin | 729 | 131 | 141 | 2.7 years | 12/131 | 17/141 | 6/131 | 9/141 | 2/131 | 11/141 | 1/131 | 0/141 | 0/131 | 0/141 |
| WARSS | 2001 | Warfarin | Aspirin | 2206 | 1103 | 1103 | 2 years | 47/1103 | 53/1103 | NA | NA | 44/1103 | 30/1103 | NA | NA | NA | NA |
| ACTIVE W | 2006 | Warfarin | DAPT | 6706 | 3371 | 3335 | 1.28 years | NA | NA | 63/3371 | 118/3335 | 93/3371 | 101/3335 | 15/3371 | 5/3335 | NA | NA |
| Vemmos et al24 | 2006 | Warfarin | Aspirin | 45 | 16 | 15 | 3.7 months | 0/16 | 0/15 | 0/16 | 2./15 | 0/16 | 0/15 | NA | NA | 0/16 | 0/15 |
| WASPO | 2007 | Warfarin | Aspirin | 75 | 36 | 39 | 1 year | 1./36 | 2./39 | 0/36 | 0/39 | 0/36 | 3./39 | 0/36 | 0/39 | NA | NA |
| BAFTA | 2007 | Warfarin | Aspirin | 973 | 488 | 485 | 2.7 years | 107/488 | 108/485 | 22/488 | 47/485 | 18/488 | 20/485 | 6/488 | 5/485 | NA | NA |
| PETRO | 2007 | Warfarin | Dabigatran | 334 | 70 | 264 | 12 weeks | NA | NA | 0/70 | 1/264 | 0/70 | 0/264 | 0/70 | 0/264 | NA | NA |
| RELY | 2009 | Warfarin | Dabigatran | 18 113 | 6022 | 12 091 | 2 years | 487/6022 | 884/12 091 | 199/6022 | 316/12 091 | 397/6022 | 697/12 091 | 45/6022 | 26/12 091 | 120/6022 | 315/12 091 |
| ARISTOTLE | 2011 | Warfarin | Apixaban | 18 201 | 9081 | 9120 | 1.8 years | 669/9081 | 603/9120 | 265/9081 | 212/9120 | 462/9052 | 327/9088 | 78/9081 | 40/9120 | 119/9052 | 105/9088 |
| ROCKET-AF | 2011 | Warfarin | Rivaroxaban | 14 264 | 7133 | 7131 | 1.9 years | 250/7133 | 208/7131 | 306/7090 | 269/7081 | 386/7125 | 395/7111 | 84/7125 | 55/7111 | 154/7125 | 224/7111 |
| J-ROCKET-AF | 2012 | Warfarin | Rivaroxaban | 1278 | 639 | 639 | 1.8 years | 5/637 | 7/637 | 22/637 | 11/637 | NA | NA | 4/637 | 3/637 | 12/639 | 6/639 |
| ENGAGE-AF | 2013 | Warfarin | Edoxaban | 21 105 | 7036 | 14 069 | 2.8 years | 839/7036 | 1510/14 069 | 337/7036 | 679/14 069 | 524/7012 | 672/14 014 | 90/7036 | 79/14 069 | 190/7012 | 361/14 014 |
| PROTECT-AF | 2013 | Warfarin | Watchman | 707 | 244 | 463 | 3.8 years | 44/244 | 57/463 | 20/244 | 29/463 | 18/244 | 22/463 | 10/244 | 3/463 | NA | NA |
| PREVAIL | 2014 | Warfarin | Watchman | 407 | 138 | 269 | 1 year | 3/138 | 7/269 | 1/138 | 7/269 | NA | NA | 0/138 | 1/269 | NA | NA |
DAPT, dual antiplatelet therapy.;
NA, not available.